Regulatory bodies like the FDA demand comprehensive characterization for any novel excipient, not just the API. For new delivery vehicles, every new lipid or protein component must be fully understood and proven safe, receiving the same level of scrutiny as the drug substance itself.
When developing a novel platform with no regulatory precedent, the key is to present a robust scientific case to agencies. This involves educating them with comprehensive data and explaining the 'why' behind your approach, rather than simply trying to fit into existing guidelines that may not apply.
Different analytical tools measure the same property, like particle size, using fundamentally different principles (e.g., DLS vs. Cryo-EM). DLS measures hydrodynamic radius in solution, while EM measures dried, shrunken particles. Scientists must understand these inherent limitations to interpret data correctly, rather than assuming one result is wrong.
Unlike academia where curiosity can be pursued broadly, industry demands a disciplined approach. It's crucial to know when to stop exploring interesting but tangential scientific paths and focus on the single most feasible route to achieve company goals, especially when faced with mixed results or limited resources.
An early career mentor in agricultural research provided a lasting lesson: publications matter, but the ultimate goal is tangible impact on people's lives. This mindset—valuing drought-resistant crops for farmers or new therapies for patients over academic metrics—is crucial for maintaining focus on what truly matters in science.